You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

319 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Guidelines and Advice
Status: Current
Version: 1
Nov 2024
Drug
Other Name(s): Sarclisa®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 1969
The resources in this toolkit will help radiologists and other imaging professionals provide consistent and high-quality imaging according to best...
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib,
riTUXimab,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: Current
ID: PET 2024-1
Mar 2025
Document
Dec 1969
Document
Dec 1969
Guidelines and Advice
Status: Current
ID: GL 20-2
Version: 2
Dec 1969
Guidelines and Advice
Status: In-Review
ID: 16-4
Dec 1969
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
Enhertu trastuzumab deruxtecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph

Pages